)

Philogen (PHIL) investor relations material
Philogen Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Announced major licensing agreements with RayzeBio (BMS) and Racebio for OncoACP3/OncoCP3, each with $350 million upfront and up to $1 billion in milestones and royalties, significantly strengthening financial resources.
Focused on advancing late-stage clinical programs, especially Nidlegy and Fibromun, and expanding the pipeline with new trials and molecules, supported by a vertically integrated R&D and manufacturing model.
Revenues from contracts with customers rose to €5.5 million, with total revenues reaching €8.7 million, up €7 million year-over-year, driven by clinical trial progress and product sales.
Expanded operations with new clinical offices in Milan, facility upgrades in Monteriggioni and Zurich, and increased research and clinical teams.
Voluntary withdrawal of Nidlegy EMA application to collect additional CMC and clinical data, with resubmission planned.
Financial highlights
Cash and cash equivalents at the end of H1 2025 were €100 million, with liquidity exceeding €350 million after major licensing inflows.
Total revenues for H1 2025: €8.7 million, up €7 million year-over-year, driven by contract manufacturing, licensing, and product sales.
EBITDA: -€13.9 million (improved from -€15.2 million in H1 2024); EBIT: -€15.8 million; net loss: €14.9 million (vs. €15.5 million in H1 2024).
Net financial position: €88.5 million surplus, with €100 million in cash and €88.8 million in liquid financial assets.
Operating costs increased 33% year-over-year, mainly due to higher R&D, clinical trial, and personnel expenses.
Outlook and guidance
Plans to invest new resources in late-stage products and launch additional global trials in non-melanoma skin cancers.
Regulatory resubmission for Nidlegy planned for mid-2026, with ongoing dialogue with authorities and US Phase III two-thirds enrolled.
Anticipates communicating first-line soft tissue sarcoma trial results and progressing glioblastoma trials in coming months.
Multiple Phase I clinical trials for new drug candidates planned over the next 24 months.
Continued collaborations with Sun Pharma, Pfizer, Janssen, Bracco, MSD, and RayzeBio.
Next Philogen earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage